Funktionsmenü_neu

Hauptnavigation

Sub-Navigation
Klickpfad

Investor News

Search

 
 

To view the PDF documents you will need the Acrobat Reader. Please click here to download the free Adobe Acrobat Reader software.

Receive our IR News via E-Mail, RSS Feed or SMS.

Thursday August 07, 2008

Bayer Schering Pharma strengthens its oncology R&D portfolio
Bayer acquires Preclinical Anti-cancer Program from Nycomed
Company assuming full development and commercialization rights

Tuesday August 05, 2008

Bayer MaterialScience raises price for MDI

Wednesday July 30, 2008

Interim report for the second quarter of 2008
Bayer continues its success
Sales up 3.6 percent to EUR 8,511 million / EBITDA before special items increases by 5.0 percent to EUR 1,896 million / EBIT before special items improves by 5.3 percent to EUR 1,248 million / Full-year guidance for CropScience raised again / Group earnings forecast confirmed

Wednesday July 30, 2008

Venous Blood Clot Prevention after Hip or Knee Replacement Surgery:
Bayer's Novel Anticoagulant Rivaroxaban Submitted for Approval in the U.S.
Rivaroxaban is first oral anticoagulant to achieve superior efficacy over the twice-daily injection of enoxaparin while maintaining low rates of major bleeding / No evidence of safety issues attributable to rivaroxaban after long-term exposure

Monday July 28, 2008

Another milestone for cancer drug from Bayer and Onyx:
Nexavar Approved for Treatment of Liver Cancer in China
Nexavar is First Approved Systemic Therapy to Treat the Disease

Friday July 25, 2008

Venous Blood Clot Prevention after Elective Hip or Knee Replacement Surgery:
Bayer's Novel Anticoagulant Rivaroxaban Recommended for Approval in the EU
Final approval from the European Commission expected within the next few months

Friday July 25, 2008

Andreas Fibig named new Chairman of the Board of Management of Bayer Schering Pharma
Dr. Bernd Metzner to become new Board member of Bayer's pharmaceuticals subsidiary / Arthur Higgins and Werner Baumann to refocus on their leadership roles in the Bayer HealthCare subgroup following the successful integration of Bayer Schering Pharma

Friday July 25, 2008

Bayer welcomes the proposed EMEA labeling changes for moxifloxacin which are consistent with existing guidelines for appropriate use of fluoroquinolone antibiotics

Tuesday July 08, 2008

Innovative active ingredient provides reliable weed protection for corn:
Tembotrione from Bayer CropScience approved in Brazil
Launch of Soberan® planned for 2008

Tuesday July 08, 2008

First organ-specific diagnostic agent approved in the U.S. in more than a decade:
Primovist® approved in the U.S. for the Detection and Characterization of Liver Lesions

Thursday July 03, 2008

Bayer CropScience strengthens global position in insecticides market:
Insecticide Movento® approved in United States and Canada
Launch of Movento® planned for 2008

Wednesday July 02, 2008

Bayer HealthCare Completes Acquisition of Western OTC Cough and Cold Business of Topsun Science and Technology
Significantly Strengthens Consumer Care Division's Business in High Growth Chinese OTC Market

Wednesday July 02, 2008

Bayer Expands Hemophilia Portfolio
Bayer HealthCare acquires hematology development portfolio featuring MAXY-VII from Maxygen
Phase 1 clinical testing expected to commence in third quarter of 2008 / Transaction includes license to Maxygen's novel biotechnology research platform

Monday June 30, 2008

Venous Blood Clot Prevention after Knee and Hip Replacement Surgery:
Rivaroxaban is First Novel Oral Anticoagulant to Significantly Reduce the Composite Outcome of Symptomatic VTE and Death
Rivaroxaban shows superior efficacy to enoxaparin for this clinical outcome with a comparable safety profile / Pre-specified analysis of pooled data from RECORD 1-3 studies involving nearly 10,000 patients

Wednesday June 25, 2008

Suspensions lifted for insecticidal seed treatment products for use in oilseed rape

Tuesday June 24, 2008

Bayer concludes supply and licensing agreements for Yasmin® and YAZ® with Barr for the United States
Appeal of court decision invalidating Yasmin patent will continue / Further growth of Bayer's Women's Healthcare Business Unit expected

Friday June 20, 2008

Bayer MaterialScience raises prices for polycarbonates

Tuesday June 03, 2008

Bayer HealthCare successfully completes acquisition of Sagmel, Inc.'s OTC Business
Bayer Consumer Care's Presence in Eastern Europe Significantly Strengthened

Monday June 02, 2008

New Nexavar® Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology (ASCO) Annual Meeting

Friday May 30, 2008

Prevention of Thromboembolism after Knee Replacement Surgery:
Rivaroxaban One Tablet/Once-Daily Superior to Twice-Daily Injectable Enoxaparin in Preventing Venous Blood Clots after Total Knee Replacement Surgery in Pivotal Phase III Trial
Rivaroxaban is First Oral Anticoagulant to Achieve Superior Efficacy over the Twice-Daily Injection of Enoxaparin while Maintaining Low Major Bleeding Rates / RECORD4 Confirms Results of RECORD1, 2 and 3 / U.S. Submission Planned for mid 2008 / Prof. Turpie: "Rivaroxaban has the potential to revolutionize the way we prevent the formation of dangerous blood clots"

Monday May 19, 2008

Amikacin Inhale shows promising results in Phase II Study
Bayer together with Nektar Therapeutics present preliminary Phase II data for the adjunctive treatment of pneumonia in intubated and mechanically-ventilated patients

Monday May 19, 2008

Reformulated Liquid Leukine® Now Available in the U.S.
EDTA removed from liquid formulation / Restoration of U.S. supplies of Leukine

Friday May 16, 2008

Bayer and Onyx Announce Nexavar® Data Presentations at 44th American Society of Clinical Oncology (ASCO) Annual Meeting

Friday May 16, 2008

Phase III Asia-Pacific Study:
Nexavar Significantly Extends Overall Survival in Liver Cancer by 47 percent
Trial Results Confirm Efficacy for Population Most Affected by the Disease

Thursday May 08, 2008

Bayer and Regeneron start additional Phase 3 Study for VEGF Trap-Eye in Wet Age-related Macular Degeneration
International study to evaluate efficacy and safety in treating a leading cause of blindness

Tuesday May 06, 2008

Bayer Schering Pharma to market new low-dose oral contraceptive YAZ® in Europe

Monday April 28, 2008

Bayer HealthCare and Regeneron Announce Encouraging 32-week Follow-Up Results from a Phase 2 Study of VEGF Trap-Eye in Age-related Macular Degeneration
Gains in visual acuity achieved in initial 12-week fixed dosing phase of study maintained in PRN (as-needed) dosing phase

Friday April 25, 2008

Werner Wenning at the Bayer AG Annual Stockholders' Meeting
"2007 was Bayer's most successful year to date"
Previous year's record levels and earnings targets exceeded / Dividend to be raised 35 percent to EUR 1.35 / Good start to fiscal 2008 / Bayer Climate Program being implemented and expanded

Thursday April 24, 2008

Interim report for the first quarter of 2008
Bayer off to an excellent start in 2008
Sales up 2.4 percent to EUR 8,536 million / EBITDA before special items up 9.8 percent to EUR 2,185 million / EBIT before special items up 8.9 percent to EUR 1,497 million / Full-year guidance for CropScience raised / Positive Group forecast confirmed

Monday April 21, 2008

Bayer Challenges Watson and Sandoz U.S. ANDA Filings on Yasmin®

Wednesday April 02, 2008

Bayer HealthCare Affiliate MEDRAD Announces Completion of Subsequent Offering Period for Shares of Possis Medical
Merger to Be Completed Shortly

Monday March 31, 2008

Bayer appeals invalidity ruling on its Yasmin® Patent
Appeal will be heard by the Federal Circuit

Wednesday March 26, 2008

Bayer HealthCare Affiliate MEDRAD Successfully Completes Tender Offer for Shares of Possis Medical; Announces Subsequent Offering Period
Subsequent Offering Period Expires on Tuesday, April 1, 2008

Tuesday March 11, 2008

Bayer HealthCare to acquire OTC Business of Sagmel, Inc.
Acquisition strengthens Bayer Consumer Care's Presence in Eastern Europe

Monday March 03, 2008

Court decides against Bayer's Yasmin® patent
Bayer HealthCare margin target (EBITDA before special items) for 2008 slightly adjusted - margin target for 2009 remains unchanged / Company will consider its legal options

Thursday February 28, 2008

Spring Financial News Conference:
Wenning: 2007 was Bayer's most successful year to date
Sales grew 11.8 percent to EUR 32,385 million / EBITDA before special items advanced 21.4 percent to EUR 6,777 million / Performance target for 2007 exceeded: underlying EBITDA margin of 20.9 percent / EBIT before special items climbed 23.2 percent to EUR 4,287 million / Group net income totaled EUR 4,711 million - boosted by divestiture proceeds / Further earnings increase expected for 2008

Tuesday February 26, 2008

Bayer proposes increased dividend for 2007 of EUR 1.35 per share

Wednesday February 20, 2008

Bayer will vigorously defend itself against Kogenate patent infringement suit filed by Novartis

Monday February 18, 2008

Bayer and Onyx Provide Update on Phase III Trial of Nexavar® in Patients with Non-Small Cell Lung Cancer

Monday February 11, 2008

Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement

Monday January 28, 2008

Nexavar® Approved for the Treatment of Kidney Cancer in Japan
First approved oral targeted therapy for metastatic RCC in Japan

Thursday January 24, 2008

Bayer extends product portfolio for liver cancer patients in Japan
Japanese authorities grant priority review status for Nexavar® in liver cancer / Launch of liver-specific contrast agent Primovist® in Japan

Wednesday January 23, 2008

Bayer establishes US special access program for Leukine® while replacing current liquid formulation
Leukine lyophilized formulation temporarily reserved for patients with Acute Myelogenous Leukemia (AML) and those experiencing bone marrow transplantation graft failure or engraftment delay / Bayer will replace current 500 mcg liquid formulation; aims to restore US supplies of Leukine to current levels as quickly as possible

Thursday January 17, 2008

US Food and Drug Administration Approves RECOTHROM

Wednesday January 09, 2008

A new high-potential biofuel crop
Archer Daniels Midland Company, Bayer CropScience and Daimler to cooperate in Jatropha biodiesel project

Thursday January 03, 2008

B-cell chronic lymphocytic leukemia (B-CLL):
Expanded Labeling for MabCampath® in Europe
Current Events
Tuesday, September 30, 2008
Meet Management in September, LeverkusenRemind
Friday, August 08, 2008
Roadshow Toronto, Canada